Comparative Effectiveness Research (CER) Specialized Registries
Texas is one of ten specialized registries with the new Comparative Effectiveness Research (CER) Specialized Registry designation. Comparative effectiveness research is designed to inform health-care decisions by providing evidence of effectiveness, benefits, and harms of different treatment options. The evidence is generated from research studies that compare drugs, medical devices, surgeries, or ways to deliver healthcare. CER Specialized Registries help address key CER questions on colorectal cancers, breast cancers, and chronic myeloid leukemia (CML). The CDC working together with the Agency for Healthcare Research and Quality (AHRQ) identified four Comparative Effectiveness Research questions to address through this effort:
- Are colorectal cancer patients tested for KRAS and are the results used appropriately to determine treatment? What impact does KRAS testing have on 2-3 year survival among colorectal cancer patients?
- Are chronic myeloid leukemia (CML) patients being tested for the BCR-ABL2 gene and receiving appropriate treatment according to those results?
- Are women with breast cancer being tested appropriately for HER2, progesterone receptor (PR), and estrogen receptor (ER) status and are they being treated appropriately?
- Are rectal cancer patients receiving radiotherapy and what is the timing of radiotherapy? Are disparities apparent in the appropriate neo-adjuvant use of radiotherapy among these patients?
Some of the major activities required by CER registries include an emphasis on data collection through data linkages, building electronic reporting capacity, and the development of non-hospital reporting sources with the goal of expanding sustainable activities to other registries over time.